Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

@article{Goy2005PhaseIS,
  title={Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.},
  author={Andre H. Goy and Anas Younes and Peter W McLaughlin and Barbara Pro and Jorge E Romaguera and Frederick B. Hagemeister and Luis E. Fayad and Nam Dang and Felipe Samaniego and Miles Wang and Kristine R. Broglio and Barry I Samuels and Frederic Gilles and Andreas H. Sarris and Susan Hart and Elizabeth G Trehu and David P. Schenkein and Fernando F Cabanillas and A. M. Herrera Rodriguez},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2005},
  volume={23 4},
  pages={667-75}
}
PURPOSE Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. PATIENTS AND METHODS Patients were stratified, based on preclinical data, into arm A (mantle-cell lymphoma) or arm B (other B-cell lymphomas) without limitation in number of prior therapies. Bortezomib was administered as an intravenous push (1.5 mg/m2) on days 1, 4, 8, and 11 every 21 days for a maximum of six cycles. RESULTS Sixty patients with a median number of… CONTINUE READING
Highly Influential
This paper has highly influenced 12 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
168 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 168 extracted citations

Similar Papers

Loading similar papers…